Resapp Health Ltd (ASX: RAP) is an upcoming mobile phone application, which aims to develop a digital healthcare app that can diagnose patients without them having to visit the doctor. The company's aim is to provide telehealth companies with point of care services that they can integrate into their platforms to make their clients lives simpler.
ResApp has yet to prove the viability of their technology and their prior clinical study earlier this year had to be thrown out as a result of poor data. The company is now trying to redo its clinical studies and ensure that it can effectively receive approval to use its technology to diagnose patients across the world. Should the company prove successful, the current value of its stock may well shoot upward in value.
Investors who have some spare cash may find ResApp a company worth considering. The company has enormous growth potential and the ability to take advantage of the trend toward technology in the healthcare, if they can execute. If you believe the management, the blotched trial is simply a minor setback.
There are no guarantees however; that the company's technology will ever be completely licensed and there is a risk the equity will become worthless.
